In contrast, RSL3 treatment has a more pronounced effect on PTKs and is able to inhibit several kinases that are involved in BCR signaling, which we previously reported to be hyperactivated in therapy-resistant MM cells [10]. The gene discussed is BCR; the disease is Miyoshi myopathy.